AustralieFrV1, PubMed, Curation, bibRecord, 002386

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Identifieur interne : 002386 ( PubMed/Curation ); précédent : 002385; suivant : 002387

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Auteurs : Martin Schlumberger [France] ; Barbara Jarzab [Pologne] ; Maria E. Cabanillas [États-Unis] ; Bruce Robinson [Australie] ; Furio Pacini [Italie] ; Douglas W. Ball [États-Unis] ; Judith Mccaffrey [États-Unis] ; Kate Newbold [Royaume-Uni] ; Roger Allison [Australie] ; Renato G. Martins [États-Unis] ; Lisa F. Licitra [Italie] ; Manisha H. Shah [États-Unis] ; Donald Bodenner [États-Unis] ; Rossella Elisei [Italie] ; Lynn Burmeister [États-Unis] ; Yasuhiro Funahashi [États-Unis] ; Min Ren [États-Unis] ; James P. O'Brien [États-Unis] ; Steven I. Sherman [États-Unis]

Source :

Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.

RBID : pubmed:26311725

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (pharmacologie), Antinéoplasiques (usage thérapeutique), Carcinome neuroendocrine (anatomopathologie), Carcinome neuroendocrine (sang), Carcinome neuroendocrine (traitement médicamenteux), Femelle, Humains, Inhibiteurs de protéines kinases (pharmacologie), Inhibiteurs de protéines kinases (usage thérapeutique), Jeune adulte, Marqueurs biologiques, Mâle, Métastase tumorale, Phénylurées (pharmacologie), Phénylurées (usage thérapeutique), Quinoléines (pharmacologie), Quinoléines (usage thérapeutique), Reprise du traitement, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Thérapie moléculaire ciblée, Tumeurs de la thyroïde (anatomopathologie), Tumeurs de la thyroïde (sang), Tumeurs de la thyroïde (traitement médicamenteux), Évolution de la maladie.
MESH :
- anatomopathologie : Carcinome neuroendocrine, Tumeurs de la thyroïde.
- pharmacologie : Antinéoplasiques, Inhibiteurs de protéines kinases, Phénylurées, Quinoléines.
- sang : Carcinome neuroendocrine, Tumeurs de la thyroïde.
- traitement médicamenteux : Carcinome neuroendocrine, Tumeurs de la thyroïde.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Phénylurées, Quinoléines.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Marqueurs biologiques, Mâle, Métastase tumorale, Reprise du traitement, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Thérapie moléculaire ciblée, Évolution de la maladie.

English descriptors

KwdEn :
- Adult, Aged, Antineoplastic Agents (pharmacology), Antineoplastic Agents (therapeutic use), Biomarkers, Carcinoma, Neuroendocrine (blood), Carcinoma, Neuroendocrine (drug therapy), Carcinoma, Neuroendocrine (pathology), Disease Progression, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Phenylurea Compounds (pharmacology), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (pharmacology), Protein Kinase Inhibitors (therapeutic use), Quinolines (pharmacology), Quinolines (therapeutic use), Retreatment, Thyroid Neoplasms (blood), Thyroid Neoplasms (drug therapy), Thyroid Neoplasms (pathology), Treatment Outcome, Young Adult.
MESH :
- chemical , pharmacology : Antineoplastic Agents, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- chemical , therapeutic use : Antineoplastic Agents, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolines.
- blood : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- drug therapy : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- pathology : Carcinoma, Neuroendocrine, Thyroid Neoplasms.
- Adult, Aged, Biomarkers, Disease Progression, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Retreatment, Treatment Outcome, Young Adult.

Abstract

Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).

DOI: 10.1158/1078-0432.CCR-15-1127
PubMed: 26311725

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002432

Links to Exploration step

pubmed:26311725

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</title>
<author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Endocrinology, Royal North Shore Hospital, Sydney</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mccaffrey, Judith" sort="Mccaffrey, Judith" uniqKey="Mccaffrey J" first="Judith" last="Mccaffrey">Judith Mccaffrey</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name>
<affiliation wicri:level="1"><nlm:affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
<wicri:cityArea>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bodenner, Donald" sort="Bodenner, Donald" uniqKey="Bodenner D" first="Donald" last="Bodenner">Donald Bodenner</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Arkansas</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name>
<affiliation wicri:level="1"><nlm:affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Burmeister, Lynn" sort="Burmeister, Lynn" uniqKey="Burmeister L" first="Lynn" last="Burmeister">Lynn Burmeister</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Minnesota, Minneapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai, Andover, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Eisai, Andover</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Eisai Inc., Woodcliff Lake</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Eisai Inc., Woodcliff Lake</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26311725</idno>
<idno type="pmid">26311725</idno>
<idno type="doi">10.1158/1078-0432.CCR-15-1127</idno>
<idno type="wicri:Area/PubMed/Corpus">002432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002432</idno>
<idno type="wicri:Area/PubMed/Curation">002386</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002386</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</title>
<author><name sortKey="Schlumberger, Martin" sort="Schlumberger, Martin" uniqKey="Schlumberger M" first="Martin" last="Schlumberger">Martin Schlumberger</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jarzab, Barbara" sort="Jarzab, Barbara" uniqKey="Jarzab B" first="Barbara" last="Jarzab">Barbara Jarzab</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cabanillas, Maria E" sort="Cabanillas, Maria E" uniqKey="Cabanillas M" first="Maria E" last="Cabanillas">Maria E. Cabanillas</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Endocrinology, Royal North Shore Hospital, Sydney</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pacini, Furio" sort="Pacini, Furio" uniqKey="Pacini F" first="Furio" last="Pacini">Furio Pacini</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ball, Douglas W" sort="Ball, Douglas W" uniqKey="Ball D" first="Douglas W" last="Ball">Douglas W. Ball</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mccaffrey, Judith" sort="Mccaffrey, Judith" uniqKey="Mccaffrey J" first="Judith" last="Mccaffrey">Judith Mccaffrey</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Newbold, Kate" sort="Newbold, Kate" uniqKey="Newbold K" first="Kate" last="Newbold">Kate Newbold</name>
<affiliation wicri:level="1"><nlm:affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Allison, Roger" sort="Allison, Roger" uniqKey="Allison R" first="Roger" last="Allison">Roger Allison</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Martins, Renato G" sort="Martins, Renato G" uniqKey="Martins R" first="Renato G" last="Martins">Renato G. Martins</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
<wicri:cityArea>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Licitra, Lisa F" sort="Licitra, Lisa F" uniqKey="Licitra L" first="Lisa F" last="Licitra">Lisa F. Licitra</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Shah, Manisha H" sort="Shah, Manisha H" uniqKey="Shah M" first="Manisha H" last="Shah">Manisha H. Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bodenner, Donald" sort="Bodenner, Donald" uniqKey="Bodenner D" first="Donald" last="Bodenner">Donald Bodenner</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Arkansas</region>
</placeName>
<wicri:cityArea>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Elisei, Rossella" sort="Elisei, Rossella" uniqKey="Elisei R" first="Rossella" last="Elisei">Rossella Elisei</name>
<affiliation wicri:level="1"><nlm:affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Burmeister, Lynn" sort="Burmeister, Lynn" uniqKey="Burmeister L" first="Lynn" last="Burmeister">Lynn Burmeister</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Minnesota, Minneapolis</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Funahashi, Yasuhiro" sort="Funahashi, Yasuhiro" uniqKey="Funahashi Y" first="Yasuhiro" last="Funahashi">Yasuhiro Funahashi</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai, Andover, Massachusetts.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Eisai, Andover</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Ren, Min" sort="Ren, Min" uniqKey="Ren M" first="Min" last="Ren">Min Ren</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Eisai Inc., Woodcliff Lake</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="O Brien, James P" sort="O Brien, James P" uniqKey="O Brien J" first="James P" last="O'Brien">James P. O'Brien</name>
<affiliation wicri:level="2"><nlm:affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Eisai Inc., Woodcliff Lake</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Sherman, Steven I" sort="Sherman, Steven I" uniqKey="Sherman S" first="Steven I" last="Sherman">Steven I. Sherman</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Biomarkers</term>
<term>Carcinoma, Neuroendocrine (blood)</term>
<term>Carcinoma, Neuroendocrine (drug therapy)</term>
<term>Carcinoma, Neuroendocrine (pathology)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Phenylurea Compounds (pharmacology)</term>
<term>Phenylurea Compounds (therapeutic use)</term>
<term>Protein Kinase Inhibitors (pharmacology)</term>
<term>Protein Kinase Inhibitors (therapeutic use)</term>
<term>Quinolines (pharmacology)</term>
<term>Quinolines (therapeutic use)</term>
<term>Retreatment</term>
<term>Thyroid Neoplasms (blood)</term>
<term>Thyroid Neoplasms (drug therapy)</term>
<term>Thyroid Neoplasms (pathology)</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Carcinome neuroendocrine (anatomopathologie)</term>
<term>Carcinome neuroendocrine (sang)</term>
<term>Carcinome neuroendocrine (traitement médicamenteux)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Inhibiteurs de protéines kinases (pharmacologie)</term>
<term>Inhibiteurs de protéines kinases (usage thérapeutique)</term>
<term>Jeune adulte</term>
<term>Marqueurs biologiques</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Phénylurées (pharmacologie)</term>
<term>Phénylurées (usage thérapeutique)</term>
<term>Quinoléines (pharmacologie)</term>
<term>Quinoléines (usage thérapeutique)</term>
<term>Reprise du traitement</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Thérapie moléculaire ciblée</term>
<term>Tumeurs de la thyroïde (anatomopathologie)</term>
<term>Tumeurs de la thyroïde (sang)</term>
<term>Tumeurs de la thyroïde (traitement médicamenteux)</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Phenylurea Compounds</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinolines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome neuroendocrine</term>
<term>Tumeurs de la thyroïde</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Neuroendocrine</term>
<term>Thyroid Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Phénylurées</term>
<term>Quinoléines</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Carcinome neuroendocrine</term>
<term>Tumeurs de la thyroïde</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome neuroendocrine</term>
<term>Tumeurs de la thyroïde</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Phénylurées</term>
<term>Quinoléines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Biomarkers</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Molecular Targeted Therapy</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Retreatment</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Marqueurs biologiques</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Reprise du traitement</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Thérapie moléculaire ciblée</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26311725</PMID>
<DateCreated><Year>2016</Year>
<Month>01</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-0432</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>22</Volume>
<Issue>1</Issue>
<PubDate><Year>2016</Year>
<Month>Jan</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
<ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.</ArticleTitle>
<Pagination><MedlinePgn>44-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-15-1127</ELocationID>
<Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Positive results of phase I studies evaluating lenvatinib in solid tumors, including thyroid cancer, prompted a phase II trial in advanced medullary thyroid carcinoma (MTC).</AbstractText>
<AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Fifty-nine patients with unresectable progressive MTC per Response Evaluation Criteria In Solid Tumors (RECIST) v1.0 within the prior 12 months received lenvatinib (24-mg daily, 28-day cycles) until disease progression, unmanageable toxicity, withdrawal, or death. Prior anti-VEGFR therapy was permitted. The primary endpoint was objective response rate (ORR) by RECIST v1.0 and independent imaging review.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Lenvatinib ORR was 36% [95% confidence interval (CI), 24%-49%]; all partial responses. ORR was comparable between patients with (35%) or without (36%) prior anti-VEGFR therapy. Disease control rate (DCR) was 80% (95% CI, 67%-89%); 44% had stable disease. Among responders, median time to response (TTR) was 3.5 months (95% CI, 1.9-3.7). Median progression-free survival (PFS) was 9.0 months (95% CI, 7.0-not evaluable). Common toxicity criteria grade 3/4 treatment-emergent adverse events included diarrhea (14%), hypertension (7%), decreased appetite (7%), fatigue, dysphagia, and increased alanine aminotransferase levels (5% each). Ret proto-oncogene status did not correlate with outcomes. Low baseline levels of angiopoietin-2, hepatocyte growth factor, and IL8 were associated with tumor reduction and prolonged PFS. High baseline levels of VEGF, soluble VEGFR3, and platelet-derived growth factor BB, and low baseline levels of soluble Tie-2, were associated with tumor reduction.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lenvatinib had a high ORR, high DCR, and a short TTR in patients with documented progressive MTC. Toxicities were managed with dose modifications and medications.</AbstractText>
<CopyrightInformation>©2015 American Association for Cancer Research.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schlumberger</LastName>
<ForeName>Martin</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave-Roussy and University Paris-Sud, Villejuif, France. martin.schlumberger@gustaveroussy.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jarzab</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Nuclear Medicine and Endocrine Oncology, Centrum Onkologii Instytut im. M. Sklodowskiei-Curie, Gliwice, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cabanillas</LastName>
<ForeName>Maria E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robinson</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pacini</LastName>
<ForeName>Furio</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Medical, Surgical and Neurological Sciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ball</LastName>
<ForeName>Douglas W</ForeName>
<Initials>DW</Initials>
<AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Johns Hopkins Medical Institute, Baltimore, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McCaffrey</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Newbold</LastName>
<ForeName>Kate</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>NIHR Royal Marsden Hospital and Institute of Cancer Research BRC, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Allison</LastName>
<ForeName>Roger</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Cancer Care Services, The Royal Brisbane and Women's Hospital, Herston, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martins</LastName>
<ForeName>Renato G</ForeName>
<Initials>RG</Initials>
<AffiliationInfo><Affiliation>Division of Clinical Research, Seattle Cancer Care Alliance, Seattle, Washington.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Licitra</LastName>
<ForeName>Lisa F</ForeName>
<Initials>LF</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Manisha H</ForeName>
<Initials>MH</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, The Ohio State University School of Medicine, Columbus, Ohio.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bodenner</LastName>
<ForeName>Donald</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Arkansas, Little Rock, Arkansas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Elisei</LastName>
<ForeName>Rossella</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burmeister</LastName>
<ForeName>Lynn</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Funahashi</LastName>
<ForeName>Yasuhiro</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Eisai, Andover, Massachusetts.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ren</LastName>
<ForeName>Min</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Brien</LastName>
<ForeName>James P</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>Eisai Inc., Woodcliff Lake, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sherman</LastName>
<ForeName>Steven I</ForeName>
<Initials>SI</Initials>
<AffiliationInfo><Affiliation>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA016672</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Cancer Res</MedlineTA>
<NlmUniqueID>9502500</NlmUniqueID>
<ISSNLinking>1078-0432</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EE083865G2</RegistryNumber>
<NameOfSubstance UI="C531958">lenvatinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C536914">Thyroid cancer, medullary</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018278" MajorTopicYN="N">Carcinoma, Neuroendocrine</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>08</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26311725</ArticleId>
<ArticleId IdType="pii">1078-0432.CCR-15-1127</ArticleId>
<ArticleId IdType="doi">10.1158/1078-0432.CCR-15-1127</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002386 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002386 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:26311725
   |texte=   A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:26311725" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki